Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To compare progression free survival (PFS) as determined by Blinded Independent Committee Review and overall survival (OS) of nivolumab combined with ipilimumab to pemetrexed plus cisplatin or carboplatin regimen as first line treatment in patients with unresectable pleural mesothelioma.
Critère d'inclusion
- Untreated unresectable Pleural Mesothelioma